ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

January 18, 2022

Red blood cell biomimetic nanoparticle with anti-inflammatory, anti-oxidative and hypolipidemia effect ameliorated atherosclerosis therapy.

Nanomedicine : Nanotechnology, Biology, and Medicine
Xiaoyu LiangYong Zeng
January 17, 2022

Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing.

Journal of Clinical and Experimental Neuropsychology
Hannah WilksJason Hassenstab
January 17, 2022

Apolipoprotein E derived from CD11c+ cells ameliorates atherosclerosis.

IScience
Manuela SauterHarald F Langer
January 17, 2022

Effects of swimming on the development of atherosclerosis in mice.

American Journal of Translational Research
Longpu ZhangDi Wu
January 17, 2022

MSR1 and NEP Are Correlated with Alzheimer's Disease Amyloid Pathology and Apolipoprotein Alterations.

Journal of Alzheimer's Disease : JAD
Justin MironPREVENT-AD research group
January 17, 2022
Review

ABCA7, a Genetic Risk Factor Associated with Alzheimer's Disease Risk in African Americans.

Journal of Alzheimer's Disease : JAD
Kaitlyn E SteplerRenã A S Robinson
January 17, 2022

Relation of middle cerebral artery flow velocity and risk of cognitive decline: A prospective community-based study.

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
Zhenxu XiaoJianhui Fu
January 17, 2022

Unusual late presentation of lipoprotein glomerulopathy recurrence in a Chinese kidney transplant recipient.

Journal of Clinical Lipidology
Chi Yuen Cheung, Wing Hung Lau
January 17, 2022

Neighborhood greenspace exposure as a protective factor in dementia risk among U.S. adults 75 years or older: a cohort study.

Environmental Health : a Global Access Science Source
Erik D SlawskyAnnette L Fitzpatrick
January 16, 2022
Preprint
Open Access

Endothelial Nitric Oxide Synthase (eNOS) S1176 phosphorylation status governs atherosclerotic lesion formation

BioRxiv : the Preprint Server for Biology
Monica Y LeeB. Sessa
January 16, 2022
Preprint
Open Access

JOINT CONTRIBUTION OF MARKERS OF NEURODEGENERATION AND HYPERCHOLESTEROLEMIA TO DEMENTIA RISK

MedRxiv : the Preprint Server for Health Sciences
Laura PernaH. Brenner
January 16, 2022

APOE4 genotype confers transcriptomic and functional alterations to primary mouse microglia.

Neurobiology of Disease
Saima I MachloviAlison M Goate
January 16, 2022

Unique B-1 cells specific for both N-pyrrolated proteins and DNA evolve with apolipoprotein E deficiency.

The Journal of Biological Chemistry
Sei-Young LimKoji Uchida
January 15, 2022

Plasma Lipocalin 2 in Alzheimer's disease: potential utility in the differential diagnosis and relationship with other biomarkers.

Alzheimer's Research & Therapy
Peter HermannFranc Llorens

Sign up to follow this feed and discover related papers.

Related Feeds

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused by a partial deletion of chromosome 22. Symptoms include heart defects, poor immune system function, a cleft palate, complications related to low levels of calcium in the blood, and delayed development. Discover the latest research on this disease here.

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

© 2022 Meta ULC. All rights reserved
/feed-previews/apoe-phenotypes/5f08b7b2-e8f9-419f-ac8f-e19485a1800c